The Effects of Intradermal Vaccination with DNA Encoding for the T-cell Receptor on the Induction of Experimental Autoimmune Encephalomyelitis in B10.PL Mice

Intradermal gene administration was found to induce a more profound immune response than direct intramuscular gene injection. We performed intradermal vaccination of B10.PL mice with DNA encoding for the Vβ8.2 region of the T-cell receptors (TCR). Three weeks later, these mice were immunized with rat myelin basic protein (MBP). Daily mean clinical scores and mortality rate were lower in this group compared with controls. The proliferative responses of lymph node cells to rat MBP were slightly less in the vaccination groups than in the control groups (p<0.05). However, we detected no differences between the two groups with regard to the production of MBP-specific IgG, IgG1, & IgG2a antibodies. The levels of cytokine mRNA expression in the vaccination groups were observed higher than in the control groups without antigen-specific stimulation, but all of cytokine expressions between the vaccination and control groups after antigen-specific stimulation were identical. These results demonstrate that intradermal DNA vaccines encoding for TCR might prove to be useful in the control of autoimmune disease.

Key Words : Vaccines, DNA; Encephalomyelitis, Autoimmune, Experimental; Injections, Intradermal; Receptors, Antigen, T-Cell; Vaccination

INTRODUCTION

T cells, which are able to recognize myelin basic protein (MBP), are thought to play a major role in the pathophysiology of experimental autoimmune encephalomyelitis (EAE). They are activated in the periphery, and then migrate to the central nervous system (CNS), inducing autoimmune inflammation culminating in motor paralysis (1). B10.PL mice, when immunized with the acetylated N-terminal MBP peptide (MBP NAc 1-9), were found to generate encephalitogenic CD4+ T cell clones, which then migrated to the CNS, inducing EAE. Approximately 85% of encephalitogenic clones express the T cell receptor (TCR) Vβ8.2 (2).

Therefore, an ideal therapy for EAE could involve selective inactivation, elimination, or functional deviation of the TCR Vβ8.2. Monoclonal antibodies targeted to pathogenic V gene products, as well as T-cell vaccination using peptides from the complementarity-determining regions of the pathogenic TCR V region, can induce resistance to the development of EAE (3). Unfortunately, peptide-based vaccines are poor immunogens (4). Genetic vaccinations with naked DNA have been reported to result in long-lasting cellular and humoral immune responses (5), and also, promote a shift in the pattern of cytokines produced by the pathogenic T cells (6).

Previous studies have indicated that intramuscular injection of Vβ8.2 DNA in PL/J mice did not exhibit suppression of EAE development when they were immunized with whole MBP (7). The possibility exists that muscle was not considered to be a viable site for antigen presentation, as it contains few, if any, dendritic cells, macrophages, and lymphocytes (8). Furthermore, it has been well established that skin-associated lymphoid tissues harbor specialized cells which enhance immune responses, and that intradermal gene administration induces more profound immune responses than does intramuscular gene delivery (5). Therefore, the in vivo transfection of epidermal or dermal cells with DNA would be expected to constitute an efficient route for gene immunization. This study was undertaken to determine the suppressive effects of intradermal gene vaccination with plasmid DNA encoding for Vβ8.2 on the clinical outcome of EAE after immunization with whole rat MBP.

MATERIALS AND METHODS

Animals

The 40 female B10.PL mice used in this study were obtain-
ed from The Jackson Laboratories (Bar Harbor, ME, U.S.A.), and bred at the Memphis Veterans Administration Medical Center Animal Research Facility. The animals were between 6 and 8 weeks old at the time of disease induction.

Antigen

MBP was prepared from frozen rat brains (Pel-Freez Biological, Rogers, AR) by the method developed by Smith (9). In brief, the dissected rat brains were homogenized in 0.32 mol/L sucrose, then layered onto 0.85 mol/L sucrose. After centrifugation (25,000 rpm for 30 min), the interface was carefully removed, washed three times with deionized water, and lyophilized overnight. The protein was then resuspended in 90% acetone and stirred for 30 min at room temperature. The precipitate was dried and redissolved in 10 mL 0.3 N hydrochloric acid. The supernatant was carefully removed, and dialyzed against 10 mM/L acetic acid. The acetic acid was removed by lyophilization, and the MBP concentration was deduced by 12% sodium dodecyl sulfate gel electrophoresis. The SDS gel was stained with Coomassie Brilliant Blue R250 solution, and destained in acetic acid/methanol. The levels were estimated based on the concentrations of the three major bands in the MBP protein (~16, ~19, and ~21 kDa) were estimated based on the concentrations of standard protein marker (GibcoBRL, Life Technologies, Gaithersburg, MD, U.S.A.).

Plasmid construction

cDNA from the 147 clone was used in this study (2). This cDNA was employed in PCR using Taq polymerase (Stratagene, LaJolla, CA, U.S.A.) with primers specific for Vβ8.2 (5′-CGG GAA TTC GCC GCC ACC ATG CAC ATG GAG GCT GCA GTC ACC CAA-3′ and 5′-TGC TCT AGA AAG TTA GCT GGC ACA GAA GTA CAC TGA-3′). These primers encompassed the entire V region (about 320 bp), and included the EcoRI and XbaI sites used in cloning. The amplified PCR products were subsequently cloned into the pcDNA3.1 eukaryotic expression vector (Invitrogen, San Diego, CA, U.S.A.), and sequenced, in order to verify the insertion of the right gene into the appropriate open reading frame.

DNA preparation and vaccination

Plasmid construct was prepared using Maxi Prep (Quiagen, Chatsworth, CA, U.S.A.). There were two groups and each group consists of twenty mice. B10.PL mice were injected intradermally with 1-mL syringes and 28-gauge needles. Intradermal inoculation was carried out 1-2 cm distal from the tail base, with 300 μg of pcDNA3.1 blank vector suspended in 100 μL PBS (control group), or an equal amount of the mixed naked DNA encoding for the TCRVβ8.2 (vaccination group). Injections took place three times, at weekly intervals.

Induction and clinical evaluation of EAE

EAE was induced by a modification of the standard protocol (10). Twenty B10.PL mice of each group received subcutaneous injections of 200 μg of rat MBP and killed Mycobacterium tuberculosis (H37RA, Difco, Detroit, MI, U.S.A.), at a concentration of 3 mg/mL, in a 0.1-mL emulsion consisting of equal volumes of 10 mM/L acetic acid and complete Freund’s adjuvant (CFA). 300 ng of Bordetella pertussis toxin (List Pharmaceuticals, Campbell, CA, U.S.A.) was administered intraperitoneally 24 and 72 hr after MBP immunizations. The mice were then observed daily for signs of EAE. The scale used to grade the clinical status of the diseased mice was as follows: 0, no clinical disease; 1, limp tail or hind limb weakness; 2, limp tail and hind limb weakness; 3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, moribund state. The mean clinical score in the study was defined as the mean clinical score of all the animals. Mortality was expressed as the percentage of animals that died as the result of severe clinical EAE. The mean day of onset indicates the mean day of the inception of signs of acute clinical disease in the mice exhibiting clinical signs. The mean peak of disease severity was evaluated as the mean of the highest clinical score achieved by the mice exhibiting clinical signs.

Determination of rat MBP-specific IgG, IgG1 and IgG2b antibodies

Blood was collected from both groups of mice three times, at weeks 0 (first immunization), 2, and 3. The rat MBP-specific IgG, IgG1, and IgG2a antibody responses were assessed by ELISA, as follows. One hundred microliters of rat MBP (5 μg/mL in 0.1 M carbonate buffer, pH 9.6) were dispensed into each well of a polystyrene microtiter plate (Costar, Cambridge, MA, U.S.A.), then incubated overnight at 4°C. The antigen-coated plates were washed three times in 0.05% PBS-Tween 20 buffer (washing buffer), and incubated with mouse sera at 4°C overnight. The plates were then washed five times with washing buffer, and incubated with peroxidase-conjugated anti-mouse IgG antibody, goat anti-mouse IgG1, and IgG2a (Sigma, St. Louis, MO, U.S.A.) overnight at 4°C. The plates were then washed five times, prior to the addition of citric acid-phosphate buffer (pH 5.0) containing 0.15 mg/mL of O-phenylenediamine (Sigma). The color was developed at room temperature, and the reaction was discontinued via the addition of 2.5 M sulfuric acid. The color was then evaluated at a wavelength of 492 nm (Bio-Rad, Richmond, CA, U.S.A.).

Lymph node cell proliferation

The proliferation assay was performed as described previ-
Intradermal Vaccination with DNA Encoding T-cell Receptor

In this study, the lymph nodes were removed 10 days after immunization with rat MBP, and single-cell suspensions were prepared. The cells (2 × 10⁶ cells per well) were then cultured with serial dilutions of rat MBP (range, 0.01-10 μg/mL). Cultures were constructed in 200 μL of RPMI1640, supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, U.S.A.), 1 mM/L sodium pyruvate, 100 μg/mL penicillin, 100 μg/mL streptomycin, 2 mM/L glutamine, 5 × 10⁻⁵ M/L 2-mercaptoethanol, 20 mM/L HEPES (pH 7.4), and 50 × nonessential amino acids. After 4 days of culturing, 1 μCi of [3H] thymidine (Du Pont, Wilmington, DE, U.S.A.) was added to each well. 18 hr later, the cells were harvested and measured via the liquid scintillation counting method. Values were expressed in counts per minute, as follows: Counts per minute with antigen – Counts per minute without antigen. Each sample was assayed in triplicate in this manner. RPMI medium 1640, sodium pyruvate, penicillin, streptomycin, glutamine, HEPES, and 50 × nonessential amino acids were purchased from Irvine Scientific (Santa Ana, CA, U.S.A.), and 2-mercaptoethanol was purchased from the Sigma Chemical Co.

Measuring the cytokine mRNA expression of lymph node cells

Lymph node cells (1 × 10⁷ cells per well) were cultured in the presence of rat MBP (100 μg/mL) in vitro for 18 hr. The cells were washed with PBS buffer, and total RNA was extracted with TRIzol Reagent (Biotecx, Houston, TX, U.S.A.). The lymph nodes were removed 10 days after immunization with rat MBP, and single-cell suspensions were prepared. The cells (2 × 10⁶ cells per well) were then cultured with serial dilutions of rat MBP (range, 0.01-10 μg/mL). Cultures were constructed in 200 μL of RPMI1640, supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, U.S.A.), 1 mM/L sodium pyruvate, 100 μg/mL penicillin, 100 μg/mL streptomycin, 2 mM/L glutamine, 5 × 10⁻⁵ M/L 2-mercaptoethanol, 20 mM/L HEPES (pH 7.4), and 50 × nonessential amino acids. After 4 days of culturing, 1 μCi of [3H] thymidine (Du Pont, Wilmington, DE, U.S.A.) was added to each well. 18 hr later, the cells were harvested and measured via the liquid scintillation counting method. Values were expressed in counts per minute, as follows: Counts per minute with antigen – Counts per minute without antigen. Each sample was assayed in triplicate in this manner. RPMI medium 1640, sodium pyruvate, penicillin, streptomycin, glutamine, HEPES, and 50 × nonessential amino acids were purchased from Irvine Scientific (Santa Ana, CA, U.S.A.), and 2-mercaptoethanol was purchased from the Sigma Chemical Co.

Table 1. The PCR conditions were as follows: 200 μM of dNTP, 10 μCi [³²P] dCTP, 50 μM Tris. HCl (pH 9.0), 50 μM NaCl, 2 μM MgCl₂, 0.5 mM DTT, and two units of Taq polymerase (Perkin Elmer) at a final volume of 20 μL. A negative control reaction was conducted with each sample, in order to verify that no PCR bands appeared in the absence of the template. The optimal amplification conditions were as follows: denaturation for 45 sec at 94 °C, annealing for 45 sec at 67 °C, and elongation for 1 min at 72 °C. Our PCR protocol called for 30 cycles. The amplified DNAs of β-actin, IFN-γ, IL-2, IL-4, and IL-5, were 340, 365, 413, 354, 349, and 455 bp in length, respectively. The gel was dried on Whatman 3M paper, then exposed to Kodak XAR film. In each run of electrophoresis, intra- and inter-gel staining homogeneity was verified via assessments of the staining intensities of the molecular weight markers at both ends of the gels. In general, the amplification kinetics for each PCR run were monitored via assessments of aliquots of the gel products. Amounts of PCR products were compared during the cycle in which the amplification did not achieve saturation.

Statistical analysis

Significance of the differences in results was determined by Student’s t-test for immunoglobulin production and proliferation assays. In order to determine the severity of disease, we utilized the Mann-Whitney test. A p value of <0.05 was considered to be statistically significant.

RESULTS

Protective effects of vaccination with Vγ8.2 on the induction of EAE disease

The control group developed a more severe course of clinical EAE than did the vaccination group. This was reflected by higher daily mean clinical score (Fig. 1) and mortality rate (50% vs. 0%) in the control group, after immunization with whole MBP. However, no differences were observed between groups with regard to the mean day of onset (21.67 ± 5.35 days vs. 18.67 ± 3.88 days), or the mean peak severity of disease (3.83 ± 1.47 days vs. 2.51 ± 0.54 days). These data suggested that intradermal vaccination with Vγ8.2 might exert a partially preventive effect on the induction of EAE disease, after immunization with whole MBP.

Table 1. Oligonucleotides used for cytokine mRNA expression in this study

| Molecules | Primer Sequence (5’ to 3’) | Product Size |
|-----------|----------------------------|--------------|
| β-actin   | 5’ GTG GGC CGC TTC AGG CAC CAA <br>3’ CTC TTT GAT GTC AGC CAC GAT TTC | 540 bp       |
| IL-2      | 5’ TTC AAG CTC CAC TTC AAG CTC TAC <br>3’ GAC AGA AGG CTA TCC ATC TCC TCA | 413 bp       |
| IFN-γ     | 5’ TGC ATG GCT TGG CAG CAC TTC <br>3’ TGG ACC TGT GGG TTG TTG ACC TCA | 365 bp       |
| IL-4      | 5’ CAG CTA GTG GTC ATG TTC CTC TCC <br>3’ GTG ATG TGG ACT TGG ACT CAT TCA TGG | 357 bp       |
| IL-5      | 5’ TGT CGT GGC CAC TGC CAT GGA GAT TC <br>3’ CCA TGT CCC ACT CGT TAC TCA CAC | 424 bp       |
MBP-specific IgG, IgG1 and IgG2a antibody production by gene vaccination

IgG1 antibody depends on the interleukin (IL)-4 which is secreted by the Th2 cells (12). Intradermal vaccination with Vβ8.2 DNA (6.75 ± 1.36 μg/mL, 7.03 ± 1.51 μg/mL) resulted in no different response with regard to MBP-specific IgG1 antibody, as compared with the control group (6.34 ± 1.08 μg/mL, 6.34 ± 0.86 μg/mL) at 2 and 3 weeks post-immunization with whole MBP (p>0.05). IgG2a antibody formation is dependent on interferon-γ (IFN-γ) as an IgM-to-IgG2a switching factor, and is believed to be a typical Th1 response (12). In regard to the response of MBP-specific IgG2a antibodies, the vaccination group (14.65 ± 1.85 μg/mL, 14.64 ± 1.98 μg/mL) did not significantly increase antibody production, in comparison with the control group (12.66 ± 1.06 μg/mL, 1.27 ± 0.22 mg/mL) and control groups (1.40 ± 0.06 mg/mL, 1.39 ± 0.06 mg/mL) with regard to the response of MBP-specific total IgG antibodies (p>0.05). Thus, intradermal genetic vaccination did not result in any differences from the control group in terms of the production of antibodies after immunization.

Cytokine gene expression by in vivo antigen stimulation

Even though the levels of mRNA expression of IFN-γ, IL-2, IL-4, & IL-5 in the vaccination group were observed higher than in the control group without antigen-specific stimulation, we detected no differences all of the cytokine expressions between the two groups after antigen-specific stimulation (Fig. 3). These data suggest that intradermal DNA vaccination with Vβ8.2 DNA might not exert any significant effects on the shift from the Th1-type cytokine to the Th2-type cytokine.

Lymph node cell proliferation

On day 10 after immunization with the rat MBP in CFA, the vaccination group’s proliferative responses to MBP of lymph node cells was found to be significantly less pronounced...
Intradermal Vaccination with DNA Encoding T-cell Receptor 1043

107 cells per well) were cultured either without antigen, or with rat MBP (100 μg/mL) in vitro, for 18 hr. The cells were washed with PBS buffer and the total RNA was extracted using TRIzol reagent. Using murine leukemia virus reverse transcriptase and random hexanucleotide primer, according to the instructions of the Perkin Elmer Gene Amp RNA PCR kit, first-strand cDNA was generated from 1 μg of total RNA and subjected to RT-PCR analysis. RT-PCR reactions were then conducted using cDNA with different primers, specific for β-actin, IL-2, γ-interferon, IL-4, and IL-5. (1) Lymph node cells from the control mice were cultured without antigen, (2) or in the presence of rat MBP (100 μg/mL). (3) Lymph node cells from the vaccinated mice were cultured without antigen, (4) or in the presence of rat MBP (100 μg/mL). The levels of mRNA expression of IFN-γ, IL-2, IL-4, & IL-5 in the vaccination groups were observed higher than in the control groups without antigen-specific stimulation, but there were no differences all of the cytokine expressions between the two groups after antigen-specific stimulation.

The results of our present study confirm the results of an earlier study, which reported that intradermal gene delivery (5) induced a more profound immune response than did intradermal cells by DNA would be expected to provide an efficient route for gene immunization, due to immune response. The present study sought to evaluate the effects of intradermal vaccination with DNA encoding for TCR Vβ8.2, on the induction of EAE in B10.PL mice, after the mice had been immunized with whole MBP. This study appears to have been extremely effective with regard to the induction of EAE after immunization, as reflected by the mean daily scores and mortality rate, even if the T-cell recognition of MBP p35-47 does not involve the Vβ8.2 gene product (14). The present study confirmed the results of an earlier study, which reported that intradermal gene administration induced a more profound immune response than did intramuscular gene delivery (5).

Although immunization with the TCR peptide (3) and vaccination with DNA (7, 15) also resulted in some protective effects on EAE development, little information is currently available regarding the mechanisms of action underlying the protection induced by DNA vaccination. A previous study reported that DNA vaccination resulted in a Th1 to Th2 cytokine shift, and then the Th2 cytokines suppressed EAE development (7). However, another previous study demonstrated that there were no signs of a Th2 cytokine bias, even if DNA vaccination did, indeed, suppress the develop-
element of EAE (16). Furthermore, myelin/oligodendrocyte
glycoprotein-induced EAE was aggravated after the induc-
tion of Th2 immunity (17). In addition, IL-4-deficient mice,
which exhibit defective Th2 responses, could be tolerant to
the induction of EAE (18). The results of a RT-PCR analysis
on the total RNA samples extracted from the lymph node
cells also demonstrated that vaccination did not induce a Th1-
to-Th2 cytokine shift. In the case of MBP-induced immune
response, we determined there to be no difference between
the vaccination and control groups with regard to the response
of IgG1 & IgG2a antibodies in the present study. This study
indicated that intradermal vaccination with DNA encoding
for TCR V8.2, in the case of EAE, did not induce a shift in
cytokine response from Th1 to Th2. Our findings were con-
sistent with other recent studies, which reported that the shift
from Th1 to Th2 cytokine responses is not directly involved
in protective effects against EAE.

In order to determine whether the observed protective
effects of gene vaccination were attributable to the deletion
of T cells or to the induction of unresponsiveness, we exam-
ined the proliferation of lymph node cells in proportion to
the MBP concentrations. In our study, we determined that
T cell proliferative responses against MBP in the vaccination
group were partially suppressed, compared to those in the
control group, but were higher in proportion to the MBP
concentration. T cell deletion has been observed primarily
after the administration of high doses of antigens or peptides
(19), and the presentation of antigens by nonprofessional
antigen-presenting cells (APCs) which lack co-stimulatory
capacity results in anergy, rather than in priming (20). How-
ever, professional APCs, Langerhans cells, or macrophages,
al of which are abundant in the dermis, may also function
as APCs after intradermal DNA vaccinations (5). It is also
possible that the intradermal gene vaccination in our study
might not have induced either T cell deletion or anergy.

Recently, it has been suggested that immunization with a
tolerogenic form of the antigen induces the generation of
regulatory CD4\(^+\)CD25\(^+\) T cells, which, when activated either
by the antigen or by anti-idiotypic-bearing transducer suppres-
sor cells, then served to mediate downmodulating T-helper
effect functions on other antigens present in conjunction with
the immunogen (21). However, the specificity or mechanisms
associated with regulatory CD4\(^+\) T cell-mediated suppression
are not currently well understood. It has been reported, from
earlier studies, that DNA vaccines are efficient inducers of
regulatory CD8\(^+\) T cell-mediated immunity, and that CD8\(^+\)
and MHC I-restricted effector T cells ultimately inhibit the
function of encephalitogenic V8.2\(^+\) T cells (22, 23). Also,
it is clear that the priming of the regulatory CD4 T cells must
occur in a Th1 milieu for the effective regulation of anti-MBP
responses, as well as protection from EAE. Furthermore, if
the regulatory CD4\(^+\) T cells are compelled to deviate in the
direction of Th2 direction, this would result in the exacer-
bation of the disease, due principally to the absence of the
natural regulation provided by MBP-reactive T cells (24).
Recent reports suggest that protection from EAE after DNA
vaccination is predicated on immunostimulatory, unmethyl-
lated CpG DNA motifs, and also that the underlying protec-
tive mechanism of DNA vaccination involves the immuno-
modulatory effects which are exerted by the induced IFN-\(\beta\),
with no evidence for a shift in immune response toward the
production of type 2 cytokines (25). Also, IFN-\(\beta\) exerts anti-
proliferative effects on peripheral blood monocytes. Our result
demonstrated that the levels of mRNA expression of IFN-\(\gamma\),
IL-2, IL-4, & IL-5 in the vaccination group were observed
higher than in the control group without antigen-specific
stimulation, but there were no differences in all of the cytokine
expressions between the two groups after antigen-specific
stimulation. This is consistent with the reports showing that
dNA vaccination activated T cells, B cells and dendritic cells
to produce a wide range of cytokines, but, DNA vaccination
induced the immunomodulation effect on the EAE after
antigen-specific stimulation (25). Therfore, we have deter-
mined that intradermal DNA vaccination does not result in
a shift from Th1 to Th2 cytokine responses, and also that T
cell proliferative responses against MBP after DNA vaccina-
tion were suppressed, as compared to what we observed in
the control group. This is consistent with earlier observations
(25). Although the observed protective autoimmune mech-
anism underlying DNA vaccination in our study have yet
to be clearly established, we suggest that the mechanisms
underlying intraderal vaccination with V8.2 DNA might
be associated with the immunomodulation exerted by the
induced IFN-\(\beta\).

In summary, genetic immunization is associated with several
advantages as compared with conventional vaccines, in that
genetic immunization makes it possible to express antigens
in forms which promote natural processing and presentation
to lymphocytes. Furthermore, DNA vaccines are safe, stable,
and induce long-lasting responses in host. Our present study
demonstrates that intraderal vaccination with DNA encoding
for the V8.2 gene of the T-cell receptor might exert
inhibitory effects on the induction of EAE in mice. This study
suggests that intraderal vaccination with DNA encoding
for TCR might constitute a useful tool in the control of auto-
immune disease.

**REFERENCE**

1. Mor F, Kantorowitz M, Cohen IR. The dominant and the cryptic T
cell repertoire to myelin basic protein in the Lewis rat. J Neurosci
Res 1996; 45: 670-9.

2. Cheng KC, Chiang HJ, Wang K, Kung MS, Yoo TJ, Hood L. TCRV
t and TCRJ gene usage in MBP responding T cells from (B10.PL \(\times\)
PL/J) F1 mice is biased towards that of B10.PL mice. J. Neuroim-
munol 1997; 80: 13-22.

3. Matsumoto Y, Tsuchida M, Hanawa J, Abo T. T cell receptor peptide
therapy for autoimmune encephalomyelitis: stronger immunization is necessary for effective vaccination. Cell Immunol 1994; 153: 468-78.
4. Bot A, Bot S, Antohi S, Karjalainen K, Bona C. Kinetics of generation and persistence on membrane class II molecules of a viral peptide expressed on foreign and self proteins. J Immunol 1996; 157: 3436-42.
5. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gronkowski SH, Singh M, Lew D, Yankauckas MA, Baird SM, Rhodes GH. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91: 9519-23.
6. Kwon SS, Kim N, Yoo TJ. The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy 2001; 56: 741-9.
7. Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, Mor F, Cohen IR, Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nature Med 1996; 2: 857-9.
8. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
9. Smith ME. An in vitro system for the study of myelin synthesis. J Neurochem 1969; 16: 83-92.
10. Watanabe T, Cheng KC, Krug MS, Yoo TJ. Brain stem auditory-evoked potentials of mice with experimental allergic encephalomyelitis. Ann Otol Rhinol Laryngol 1996; 105: 905-15.
11. Chen KC, Lee KM, Krug MS, Watanabe T, Suzuki M, Choe IS, Yoo TJ. House dust mite-induced sensitivity in mice. J Allergy Clin Immunol 1998; 101: 51-9.
12. Gorelik L, Flavell RA. Abrogation of TGF-beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-81.
13. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
14. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32: 121-82.
15. Lobell A, Weisert R, Storch MK, Svanholm C, de Graaf KL, Lassmann H, Andersson R, Olsson T, Wigzell H. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc receptor of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J Exp Med 1998; 187: 1543-8.
16. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linton C, Raine CS, Hauser SL. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054-7.
17. Marusic S, Tonegawa S. Tolerance induction and autoimmune encephalomyelitis amelioration after administration of myelin basic protein-derived peptide. J Exp Med 1997; 186: 507-15.
18. Singer GG, Abbas AK. The Fox antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunol 1994; 1: 365-71.
19. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19: 89-97.
20. Kumar V, Sercarz E. Self-determinant selection and selective regulation. Chem Immunol 1995; 60: 1-19.
21. Tartado GC, Olives-Villagomez D, Curotto de Lafaille MA, Wensky AK, Latkowski J, Lafaille JI. Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 2001; 182: 122-34.
22. Mathisen PM, Tuothy VK. Gene therapy in experimental autoimmune encephalomyelitis. J Clin Immunol 2000; 20: 327-33.
23. Jiang H., Curran S, Ruiz-Vazquez E, Liang B, Winchester R, Chess L. Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor Vβ repertoire during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2003; 100: 8378-83.
24. Braciak TA, Pedersen B, Chin J, Hsiao C, Ward ES, Mariic I, Jahng A, Graham FL, Gauldie J, Sercarz EE, Kumar V. Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the Vβ8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or IL-10. J Immunol 2003; 170: 765-74.
25. Wefer J, Harrissa RA, Lobell A. Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFN-β. J Neuroimmunol 2004; 149: 66-76.